Latest Breaking News On - Late breaking - Page 3 : vimarsana.com

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress - Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology.

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions

Study participants may transition from the rivaroxaban arm to abelacimab in an extension study 

Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023

Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023

New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema Real-world data reinforce that.

F. Hoffmann-La Roche Ltd: New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

New Clinical and Real-World Data for Genentech's Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p.